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Background/aim: Our aim in this study was to compare the efficacy and safety of crystalloid del Nido solution and cold blood
cardioplegia solution on clinical and laboratory parameters.
Materials and methods: Sixty patients who underwent elective coronary bypass operation between July 2019 and January 2020 were
included in our study. Patients were divided into 2 groups of 30 patients using del Nido solution (DNS) and cold blood cardioplegia
solution (CBCS), which were given for cardiac arrest. Demographic data, preoperative, postoperative 0th h, 6th h and 4th day creatine
kinase myocardial band (CK-MB) and troponin I values were compared with a specific cardiac enzyme heart-type fatty acid-binding
protein (H-FABP).
Results: We found that aortic cross clamp duration and cardiopulmonary bypass (CPB) time were shorter in patients using del Nido
solution than cold blood cardioplegia solution (57.30 ± 23.57 min, 76.07 ± 27.18 min, P = 0.006) (95.07 ± 23.06 min, 114.13 ± 33.93, P =
0.014). Total cardioplegia solution volume was higher in the cold blood cardioplegia solution group (1426.67 ± 416.00 vs. 1200 ± 310.73
P = 0.02). Preoperative and postoperative levels of cardiac enzymes including CK-MB, troponin I and H-FABP were comparable in del
Nido solution and cold blood cardioplegia solution groups.
Conclusion: According to these results, when we compare both demographic data and CK-MB, troponin I and H-FABP levels, both
cardioplegia solutions were comparable regarding safety and efficacy in terms of myocardial protection.
Keywords: Heart-type fatty acid-binding protein, cold blood cardioplegia solution, del Nido solution, coroner artery bypass grafting,
myocardial protection

1. Introduction
Myocardial damage during cardiac surgery is the most
important cause of mortality and morbidity. Cardioplegia
has been used for many years in cardiac surgery for
myocardial protection due to systemic and local
hypothermia [1,2]. Cardioplegia solution, which is the
technique of providing elective and chemically cardiac
arrest, was first applied in 1955 by Melrose with potassium
[3]. As open heart surgery develops structurally and
physiologically, it has led to the development of new
types of cardioplegia solution. In 1990, Dr. del Nido and
researchers at the University of Pittsburg developed a
cardioplegia solution, a mixture of long-acting blood and
crystalloids, especially for pediatric patients. Changes have

been made in the original solution, and is currently known
as “del Nido cardioplegia solution” in the clinical practice
[4]. The addition of polarizing agents such as lidocaine
is thought to reduce the energy consumption, and the
presence of calcium-competing ions such as magnesium
at optimum concentration reduce intracellular calcium
concentration, thereby preventing the cell damage [5].
In the literature, there are many studies showing the
safety and efficacy of adult cardiac surgery with del Nido
cardioplegia solution [6–11].
Heart-type fatty acid binding protein (H-FABP) is
a small cytoplasmic protein (15 kDa) and is expressed
2–10 times more in the cardiac muscle than in the skeletal
muscle. Its physiological functions are the protection
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of cells during ischemia through the transport of fatty
acids, the synthesis of membranes and mediators, gene
expressions, and inactivation of the radicals [12–14].
Following myocardial damage, it enters the circulation
rapidly and reaches high concentrations in the serum
within 1 h after myocardial injury [15,16]. H-FABP has
been accepted as an early marker for acute myocardial
infarction (MI), but is not yet common in clinical use
[17]. Cardiac troponins are specific markers for MI and
are mainly released from the necrotic cardiac myocytes
[18]. H-FABP is also released from the necrotic cardiac
myocytes, but unlike troponin, it is released from the
ischemic cardiac myocytes as well [19–21].
Our aim in this study was to compare the serum
H-FABP, creatine kinase myocardial band (CK-MB)
and troponin I levels following the administration of
crystalloid del Nido solution and the traditional cold blood
cardioplegia solution for cardiac arrest during coronary
bypass operation.
2.Materials and methods
2.1. Patients
The study was approved by the Institutional Ethics
Committee (approval date: July 03, 2019, document
number: 3). Before participation in the study, informed
written consent was obtained from each subject after
explaining the protocol.
A total of 60 patients who underwent elective coronary
artery bypass operation in the Cardiovascular Surgery
Department of Kahramanmaraş Sütçü İmam University
Research Hospital between July 2019 and January 2020
were included in the study. They were randomly divided
into 2 groups of 30 patients. The first group was composed
of patients using del Nido cardioplegia solution (group
DNS) for cardiac arrest during the operation, and the
second group was composed of patients with traditional
cold blood cardioplegia solution (group CBCS). All patients
were operated with cardiopulmonary bypass (CPB)
under general anesthesia. The patients with reoperation
due to bleeding, acute MI, congenital heart disease,
cardiomyopathy, valvular heart disease, congestive heart
failure, malignancy, infectious diseases, acute or chronic
inflammatory diseases, psychiatric diseases, neurological
diseases, hematological diseases, renal failure, liver failure
and hematological diseases were excluded from the study.
2.2. Anesthesia technique
Standard anesthesia at therapeutic doses was applied to
all patients. Radial artery catheterization was performed
and monitored. Induction of anesthesia was achieved with
midazolam (Zolamid®, Defarma, Tekirdağ, Turkey, 0.1
mg/kg, intravenously), fentanyl (Talinat®, Vem, İstanbul,
Turkey, 5–8 mcg/kg, intravenously) and rocuronium
bromide (Myocron®, Vem, 0.6 mg/kg, intravenously).

1000

General anesthesia was achieved with anesthesia device
(Drager, Lubeck, Germany), and anesthetic agent 2 %
MAC (Minimum alveolar concentration) Sevoflurane
(Sevorane®, Abbvie, İstanbul, Turkey). Rocuronium
bromide (0.6 mg/kg, intravenously) was administered
every 30 min.
2.3. Surgical technique
All surgical procedures were performed in mild
hypothermia (32 oC), accompanied by aortaatrial
cannulation, with CPB, with the help of nonpulsatile ruller
pump, membrane oxygenator and standard extracorporeal
circuits. To keep the activated clotting time (ACT) value
above 480 s, 320–400 IU/kg unfractionated heparin was
administered intravenously. 1350 mL prime volume (1
L isolate S, 20% mannitol 200 cc, 3% NaCl 150 cc, 5000
IU heparin) were taken into the pump lines. During the
cardiopulmonary pump, 2.0–2.5 L/min/m² flow rate,
mean arterial pressure 60–80 mmHg, 180–200 mm Hg
PaO2 and 35–45 mmHg PCO2 were maintained. Body
temperature adjustment was cooled at a rate of 1 °C per
min and was performed by reheating at a rate of 1 °C
every 3 min. Antegrade cardioplegia cannula was placed
in the ascending aorta. Following aortic clamp, 1000
mL del Nido cardioplegia solution was given once at +4
°C. An additional dose was administered if the del Nido
cardioplegia solution exceeded 60 min.
Conventional cold blood cardioplegia solution
was given as 1000 mL at 32 °C. In the ischemic period,
an additional 500 mL dose was administered every 20
min. Before opening the aortic cross clamp (ACC),
approximately 500 mL of warm blood (hot shot; 37 °C)
was applied through an antegrade cardioplegia catheter
to facilitate spontaneous heart contraction. Proximal
anastomoses were performed with a side clamp on the
ascending aorta. After the CPB was over and the cannulas
were removed, the unfractionated heparin was neutralized
with protamine.
Del Nido cardioplegia solution and the traditional cold
blood cardioplegia solution contents were shown in Table 1.
2.4. Laboratory measurements
Cardiac troponin I and CK-MB values were measured in
preoperative, postoperative 0th h, 6th h and 5th day blood
samples. In addition, preoperative, postoperative 6th h and
postoperative 5th day blood samples were taken to search
for H-FABP values. Serum and plasma were separated for
H-FABP examination and stored at −80 °C for analysis.
Serum CK-MB and troponin I levels were studied on
Roche Cobas 8000 automatic analyzer. Results for CK-MB
and troponin I were determined as μg/L.
Serum H-FABP levels (Bioassay Technology
Laboratory, Shanghai, China) were studied using the
ELISA (enzyme-linked immunosurbent assay) method,
automatic ELISA reader (Thermo Fisher Scientific, Vantaa,
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Table 1. The components of the solution used in the del Nido and cold blood cardioplegia.
Variables components

DNS

CBCS

Basic solution

İsolayt S* 1 L

Blood, 1 L

KCL (mEq/L)

26

22.5 for induction 7 to remain

NaHCO3 (mEq/L)

13

10

% 20 Mannitol (mL)

17

20

% 15 MgSO4 (mL)

14

10

% 2 Lidocaine (mL)

6,50

0

Blood/crystalloid rate

1/4

4/1

DNS: Del Nido solution, CBCS: Cold blood cardioplegia solution, * İsolayt S (Na:141mEq,
K: 5 mEq, Mg: 3 mEq, Cl: 98 mEq, Asetat: 27 mEq, Fosfat: 1 mEq, Glukonat: 23 mEq, pH
7.40), NaHCO3: Sodium bicarbonate, KCL: Potassium chloride, MgSO4: Magnesium
sulfate.

Finland) and computer program (Scanlt for Multiscan FC
2.5.1). For H-FABP: Sensitivity: 0.01 μg/mL, Assay range:
0.05 μg/mL–20 μg/mL, intraassay coefficient of variation
(CV) % <8%, and interassay % CV <10%. The results were
determined as μg/ml.
2.5. Statistical analysis
The suitability of the variables to normal distribution
was examined with the Shapiro-Wilk test. Comparisons
between groups were evaluated with the independent
samples t test. Covariance Analysis (ANCOVA) was
applied to compare group differences in postoperative
measurements independently of preoperative differences.
Frequency distribution differences between categorical
variables were performed with chi-square test and Fisher’s
exact test. Statistical significance was accepted as P < 0.05.
Data was evaluated in IBM SPSS version 22.0.
3. Results
The demographic data of the patients were given in table
2. There was no difference in demographic characteristics
between the 2 groups. All intraoperative data and
postoperative clinical results were presented in Table 3.
Aortic cross clamp (ACC) time and CPB time was shorter in
patients using del Nido cardioplegia solution (group DNS)
than in the group using cold blood cardioplegia solution
(group CBCS) (57.30 ± 23.57 minutes, 76.07 ± 27.18 min, P
= 0.006 and 95.07 ± 23.06 min, 114.13 ± 33.93, P = 0.014).
The total volume of cardioplegia solution used was 1200 ±
310.73 mL in the group using DNS and 1426.67 ± 416.00
mL in the group using CBCS, and there was a significant
difference between the groups (P = 0.02). The number of
grafts with coronary bypass was 3.57 ± 0.90 in group DNS,
3.77 ± 0.86 in group CBCS and there was no significant
difference between groups (P = 0.383). Postoperative atrial
fibrillation (AF) was developed in nine patients in Group

DNS, and 5 patients in the group CBCS. When 2 groups were
compared, there was no statistically significant difference
between the 2 groups, although more patients developed
postoperative AF in group DNS (P = 0.222). Postoperative
low cardiac output syndrome (LCOS) was developed in 2
patients in group DNS, and in 1 patient in group CBCS,
there was no statistically significant difference (P = 0.554).
In-hospital mortality was developed in 2 patients in Group
DNS, and 1 patient in group CBCS, and there was no
statistically significant difference between groups in terms
of mortality (P = 0.554). There was no significant difference
between groups in developing postoperative renal failure (P
= 0.554). When intraoperative defibrillation requirements
were compared, there was no significant difference (P =
0.640). There was no significant difference between the
groups in terms of intensive care stay and hospital stay
(P = 1.000 and P = 0.524, respectively). Preoperative and
postoperative (0. h, 6. h and 5. day) CK-MB and troponin
I levels, and preoperative and postoperative (6. h and 5.
day) H-FABP results were presented in Table 4. When the 2
groups were compared, there was no statistically significant
difference in CK-MB, troponin I and H-FABP values.
4. Discussion
This study was performed to investigate the effectiveness
of 2 different cardioplegia solutions used for cardiac
arrest during coronary bypass surgery. We evaluated the
myocardial protection by measuring the cardiac enzymes
CK-MB and troponin I, compared to H-FABP, which
is sensitive and fast-releasing biomarker for myocardial
damage. Both crystalloid-based or blood-based, all methods
of cardioplegia work for hyperkalemic electromechanical
diastolic arrest. Our aim was to provide a clear still vision
in our surgical field, and to protect the myocardium from
ischemic damage as much as possible.
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Table 2. The baseline features of the patients included in the present study.
Group DNS (n = 30)

Group CBCS (n = 30)

P value

Sex (Female/male)

10/20

8/22

0.57

BMI, kg/m

29.82 ± 3.02

30.15 ± 3.11

0.68

Age, years

59.03 ± 11.58

62.00 ± 11.53

0.62

Diabetes mellitus

12 (40.00%)

14 (46.67%)

0.60

Hypertension

14 (46.67%)

13 (43.33%)

0.80

Hyperlipidemia

10 (33.33%)

12 (40.00%)

0.59

Peripheral artery disease

6 (20.00%)

8 (26.67%)

0.54

Chronic renal failure

0 (0.00)

0 (0.00)

-

Chronic obstructive pulmonary diseases

5 (16.67%)

6 (20.00%)

0.74

Smoking

8 (26.67%)

9 (30.00%)

0.77

Ejection fraction

52.33 ± 8.38

52.97 ± 10.00

0.79

2

Independent samples t test; Chi-Square test; Fisher’s exact test; α: 0.05; DNS: Del Nido solution; CBCS: Cold blood
cardioplegia solution; BMI: Body mass index; SD: Standart deviation. Note: Values are presented as mean ± SD and
percentage.
Table 3. The intraoperative data and postoperative outcomes.
Group DNS

Group CBCS

P value

Bypass number

3.57 ± 0.90

3.77 ± 0.86

0.38

Cross time, min

57.30 ± 23.57

76.07 ± 27.18

0.01*

Cardiopulmonary bypass time, min

95.07 ± 23.06

114.13 ± 33.93

0.01*

Total cardioplegia volume, mL

1200.00 ± 310.73

1426.67 ± 416.00

0.02*

Postoperative renal failure

2 (6.67%)

1 (3.33%)

0.55

Postoperative atrial fibrillation

9 (30.00%)

5 (16.67%)

0.22

Mortality

2 (6.67%)

1 (3.33%)

0.55

Low cardiac output syndrome

2 (6.67%)

1 (3.33%)

0.55

Intensive care stay time, days

2.23 ± 0.68

2.23 ± 0.43

1.00

Hospitalization time, days

7.11 ± 0.63

7.00 ± 0.64

0.52

Intraoperative defibrilation

3 (10.00%)

2(6.67%)

0.64

Independent samples t test; Chi-Square test; Fisher’s exact test; α: 0.05; DNS: Del Nido solution; CBCS:
Cold blood cardioplegia solution. Note: Values are presented as mean ± SD and percentage.

In our study, patients were divided into 2 groups each
consisted of 30 patients according to the solutions used for
cardiac arrest: the group using CBCS and the group using
DNS. When these 2 groups were compared, there was no
difference in terms of demographic data. The absence of
significant differences in demographic data between the
2 groups indicates that the groups were homogenized.
This enables us to obtain more accurate results in order
to compare the heart-protective effect of 2 cardioplegia
methods in our study. Del Nido cardioplegia solution is
repeated every 60 min, it may be repeated once every 90
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min in several clinics [22,23]. We found that cross clamp
time and CPB time in del Nido cardioplegia solution group
were lower than the group using cold blood cardioplegia
solution. We think that this is due to the differences in
administration intervals, since del Nido cardioplegia
solution was given once every 60 min, while cold blood
cardioplegia solution was given once every 20 min.
Administration of cold blood cardioplegia solution every
20 min increases the volume of cardioplegia solution. In the
study performed by Ucak et al., in patients who underwent
coronary bypass by using del Nido cardioplegia solution
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Table 4. The mean levels of preoperative and postoperative cardiac enzymes and H-FABP.

H-FABP (μg/ml)

CK-MB (ng/mL)

Troponin I (ng/mL)

Group DNS

Group CBCS

P value

Preoperative

5.49 ± 1.46

5.54 ± 1.51

0.90a

Postoperative 6th hy

6.47 ± 1.65

6.23 ± 1.13

0.29b

Postoperative 4th dayz

6.52 ± 1.72

6.44 ± 1.57

0.89b

Preoperative

2.30 ± 0.87

2.33 ± 0.75

0.90a

Postoperative 0th hx

28.37 ±7.46

28.83 ± 8.04

0.92b

Postoperative 6th h

31.83 ± 5.99

32.47 ± 6.10

0.70b

Postoperative 4th day z

3.28 ± 1.45

3.38 ± 1.34

0.87b

Preoperative

0.04 ± 0.03

0.04 ± 0.02

0.63a

Postoperative 0th hx

3.12 ± 1.24

3.24 ± 1.17

0.71b

Postoperative 6th h

5.91 ± 1.81

5.83 ± 1.63

0.95b

Postoperative 4th dayz

0.65 ± 0.35

0.66 ± 0.27

0.99b

y

y

Independent samples t test; bCovariance analysis (ANCOVA); α: 0.05; x(Dependent variable: Postoperative 0th
h, Covariate: Preoperative); y(Dependent variable: Postoperative 6th h, Covariate: Preoperative, postoperative
0th h); z(Dependent variable: Postoperative 4th day, Covariate: Preoperative, postoperative 0th h, postoperative
6th h); DNS: Del Nido solution; CBCS: Cold blood cardioplegia solution; H-FABP: Heart-type fatty acidbinding protein; CK-MB: Creatine kinase-MB. Note: Values are presented as mean ± SD.
a

and blood cardioplegia solution, the cross clamp time
and total CPB durations were shorter, and total volume
of cardioplegia solution was less in del Nido cardioplegia
solution, similar to our study [24]. In our study, there was
no statistically significant difference between the groups
in terms of intraoperative defibrillation requirement,
LCOS, postoperative AF, postoperative kidney failure,
intensive care stay and hospitalisation. In a meta-analysis
performed by Guru et al., they showed that patients with
blood cardioplegia solution had lower postoperative LCOS
and lower mean postoperative CK-MB values compared
with patients using crystalloid cardioplegia solution [25].
In another meta-analysis performed by Sa et al., they
showed that there was no significant difference between
patients using crystalloid cardioplegia solution and those
with blood cardioplegia solution in terms of developing
LCOS [26].
Increased CK-MB and troponin I values in the
postoperative period estimate the myocardial damage in
patients undergoing cardiac arrest with CPB [27]. In our
study, there were no difference in CK-MB and troponin
I levels between the groups, which were examined
consecutively. Jonge et al. showed in their 12-year
retrospective research that the postoperative mean CKMB value of patients using blood cardioplegia solution was
significantly higher than that of crystalloid cardioplegia
solution [28]. Ucak et al examined postoperative CKMB and troponin I levels in isolated coronary bypass
operations using del Nido solution and blood cardioplegia
solution. They showed that there was no significant

difference between the 2 groups between the mean CK-MB
and troponin I levels [24]. In the meta-analysis conducted
by Li et al., over a number of 836 patients using del Nido
cardioplegia solution and traditional blood cardioplegia
solution were compared. They showed that there was no
difference between the 2 groups in terms of postoperative
mortality, development of atrial fibrillation (AF), levels of
CK-MB, troponin I and troponin T [29].
H-FABP is placed in the cytoplasm of striated muscle
cells and is rapidly released in response to myocardial
damage [30]. Upon myocardial damage, H-FABP
is quickly released from myocytes into the systemic
circulation due to its small size and free cytoplasmic
localization. It has been suggested that transient increases
in sarcolemmal membrane permeability allowed H-FABP
escape into the systemic circulation. Previous studies
claimed that myocyte damage may occur even after shortterm ventricular stress [31,32]. H-FABP has a potential
role in cardiomyocyte differentiation. Its relationship with
decreased cell proliferation in the mice cardiomyocytes
have been demonstrated by in vivo and in vitro studies
[33,34]. Wang et al. indicated that overexpression of
H-FABP inhibited cell proliferation in bone marrowderived mesenchymal stem cells [35]. In addition, Zhu et
al. demonstrated that P19 embryonic myocardial cell line
that overexpresses H-FABP inhibited cell proliferation and
promoted apoptosis during myocardial cell development
[36]. In ventricular myocytes of newborn rats under
hypoxia, down regulation of H-FABP suppressed cell
apoptosis and improved structural remodeling. Besides,
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H-FABP upregulation has been shown to increase the
phosphorylation in mitogen activated protein kinases
(MAPK) signaling pathway and decrease phosphorylated
protein kinase B (Akt) levels, thus, leading an increase in
apoptosis and in remodeling [37]. Elimination of H-FABP
occurs through the kidney, hence, creates a diagnostic
window for patients with normal kidney function [38].
In previous studies, H-FABP has been shown to
function as a reliable diagnostic marker in patients with
acute coronary syndrome, peripheral vascular ischemia,
cardiac surgery, and coronary artery surgery [39–42].
Our study is the first assay in the literature to compare the
effect of 2 different cardioplegia solutions on myocardial
protection by meausring serum H-FABP levels. H-FABP
acts as a transporter of myocardial fatty acids, and is
released into the circulation immediately after myocardial
damage. H-FABP is a more sensitive biomarker that shows
a much faster increase than CK-MB and troponin I, the
biomarkers showing myocardial damage after coronary
bypass [43,44]. Thielman et al. evaluated the troponin I
and H-FABP levels at 1st, 6th, 12th, 24th, 48th, and 72th
h postoperatively to determine the myocardial damage
in patients undergoing coronary bypass. They showed
that the rapid increase in serum H-FABP values is a more
specific biomarker in determining the perioperative
myocardial damage [44]. Jo et al. showed that H-FABP was
more sensitive than CK-MB and troponin T to postulate
the myocardial damage in patients undergoing cardiac
surgery with CPB [45]. Assuming that H-FABP is superior
to conventional cardiac biomarkers to predict early
perioperative myocardial damage after coronary artery
bypass graft (CABG) surgery, we analyzed the serum
levels of H-FABP at preoperative, postoperative 6th h and
4th day to compare the effect of 2 different cardioplegia
solution. According to our findings, the mean H-FABP
value did not differ significantly in all time periods using

both cardioplegia solutions. Hence, both cardioplegia
solutions we used seem reliable in terms of myocardial
protection due to CK-MB, troponin I and H-FABP levels.
In conclusion, our clinical and laboratory results
were very satisfactory using DNS in patients undergoing
CABG surgery. The results of our study showed that
both del Nido cardioplegia solution and traditional cold
blood cardioplegia solution that we routinely used in our
clinics were effective and usable. In many respects, both
methods are close to each other and do not provide any
obvious superiority. In addition to the common cardiac
enzymes CK-MB and troponin I, H-FABP, which is a more
sensitive enzyme against cardiac ischemia, showed that 2
cardioplegia methods were both safe and effective. This
study is a single-center study focusing on the clinical results
of a limited number of adult coronary surgical cases. It is
not possible to reveal a general conclusion based solely on
these results. Further studies on myocardial cells, especially
at the molecular level, would provide more informative
data on the importance of the use of cardioplegic methods
in the future. Our results are encouraging for the further
studies.
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